G Protein-Coupled Receptors (GPCRs) in advancing GPCR-targeted therapies, including the use of agonists, antagonists, biased ...

a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its PAR2 biased negative allosteric modulator program Posters present the potential ...

Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology ...

By leveraging Domain’s expertise to address challenging GPCRs, DT-9046 represents a groundbreaking advancement in PAR2 modulation employing a differentiated mechanism of action, targeting an ...

DT-9046 represents a groundbreaking advancement in PAR2 modulation employing a differentiated mechanism of action, targeting an allosteric binding site to fine-tune GPCR function and boost ...

Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This ...